The Deerfield, Ill.-based company said that it offered $841.3 million (EU €750 million) in 0.4% senior notes due 2024 and $841.3 million (EU €750 million) in 1.3% senior notes due 2029.
The senior notes were sold pursuant to an underwriting agreement inked last week between Baxter, Barclays Bank, Citigroup Global Markets Limited, Merrill Lynch International and other underwriters, according to an SEC filing.
Baxter has not yet stated how it plans to spend funds raised in the offering.
Late last month, Baxter saw share prices dip despite the medical device maker beating expectations on Wall Street with its first quarter 2019 earnings.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.